Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2016 / Article

Corrigendum | Open Access

Volume 2016 |Article ID 7173896 | https://doi.org/10.1155/2016/7173896

Barbara Grube, Udo Bongartz, Felix Alt, "Corrigendum to “IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety”", Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 7173896, 1 page, 2016. https://doi.org/10.1155/2016/7173896

Corrigendum to “IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety”

Received18 Oct 2016
Accepted16 Nov 2016
Published29 Dec 2016

In the article titled “IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety” [1], there was an error under Section : Hip Circumference, which should be corrected as follows.

3.1.3. Hip Circumference. The mean hip circumference in the IQP-VV-102 group at baseline (V2) was 108.1 cm (SD 6.7) while the placebo group was 106.5 cm (SD 6.5) ().

In addition, the declaration statement in the Conflict of Interests section “The authors declare that there is no conflict of interests regarding the publication of this paper” should be replaced with the following declaration “InQpharm Europe Ltd. is the manufacturer of the investigational product and oversaw the trial and manuscript preparation as the sponsor.”

References

  1. B. Grube, U. Bongartz, and F. Alt, “IQP-VV-102, a novel proprietary composition for weight reduction: a double-blind randomized clinical trial for evaluation of efficacy and safety,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 413075, 7 pages, 2015. View at: Publisher Site | Google Scholar

Copyright © 2016 Barbara Grube et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

773 Views | 239 Downloads | 0 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.